Elaine Walsh, PhD
Medical Oncology · Washington, DCNPI 1780104570
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,438 of the $1,820 with a category attached, or 79.0%. Pfizer accounts for 80.6% of it on its own, with 10 other manufacturers making up the rest. That places this record below the midpoint for medical oncology clinicians in DC, where the typical reported total is $1,820.
Across 16 payments — averaging $113.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Beone Medicines USA, Inc.$57
- Johnson & Johnson$50
- Merck$47
- AstraZeneca$42
- Exelixis Inc.$34
- plus $122 from 5 others
Across 21 payments — averaging $19,381 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$265K
- Pfizer$110K
- Jazz Pharmaceuticals Inc.$32K
What the payments were for
- Speaking & faculty fees$1,43879%
- Food & beverage$38221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 2 | $1,467 |
| Beone Medicines USA, Inc. | 2 | $57 |
| Johnson & Johnson | 2 | $50 |
| Merck | 2 | $47 |
| AstraZeneca | 2 | $42 |
| Exelixis Inc. | 1 | $34 |
| Genmab U.S., Inc. | 1 | $31 |
| Novartis | 1 | $27 |
| Genentech USA, Inc. | 1 | $24 |
| Incyte Corporation | 1 | $21 |
| Accord Healthcare, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TUKYSA$1,438
How this compares
$1,820 in reported general payments places this provider in the 50th percentile of 29 medical oncology providers in District of Columbia.
See all medical oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 67 | $2,018 |
| Anastrozole | 15 | $285 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Washington
- Nancy DawsonWashington$1.7M
- Joshua ReussWashington$218K
- Pashna MunshiWashington$189K
- Michael PishvaianWashington$147K
- Kieron DunleavyWashington$139K
- Asim AminWashington$120K
- Mitchell SmithWashington$41K
- Channing PallerWashington$33K
- Solmaz SahebjamWashington$31K
- Khaled El-ShamiWashington$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.